Handelsavisen
prelaunch
Companies ›Healthcare ›6978.HK
69
6978.HK — HKEX Biotechnology & Medical Research

Immunotech Biopharm Ltd

HK$0,74
Open in Charts → Attach watcher ⌖
— —
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
1 657,1 %
Net margin
—
Debt / equity
-31,61
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Immunotech Biopharm Ltd is a biotechnology company engaged in pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biopharmaceutical products.

Business. Immunotech Biopharm Ltd (6978.HK) is a biotechnology and medical research company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not provided in the available data. Consequently, the company is described at the industry level as a participant in the biotechnology and medical research field.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
1 657,1 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6978.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6978.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Immunotech Biopharm Ltd (6978.HK) is a biotechnology and medical research company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not provided in the available data. Consequently, the company is described at the industry level as a participant in the biotechnology and medical research field.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Immunotech Biopharm Ltd has a negative equity position of CNY -13.93 million, indicating a significant financial challenge, and a debt-to-equity ratio of -31.61, which suggests that the company is financed almost entirely by debt. The company's liquidity is rated as medium, with a current ratio of 0.35, which is below the typical threshold for financial health, indicating that the company may struggle to meet its short-term obligations.

    The company's profitability is weak, with a net loss of CNY -230.79 million and an operating loss of CNY -222.89 million, which is far below the industry median for profitability metrics. The return on assets is negative at -0.3828, and the return on equity is 16.571, which is unusually high given the negative equity, suggesting that the company is not effectively utilizing its assets to generate profit.

    Immunotech Biopharm Ltd's revenue is reported as CNY 0.0, indicating that the company is not currently generating revenue from its operations. The company's financial snapshot does not provide segment or geographic revenue breakdowns, so it is unclear where the company's exposure lies.

    The company's growth trajectory is not evident from the provided data, as there is no revenue history to analyze. The company's outlook for the current and next fiscal years is not provided, but the negative operating and net income suggest a challenging period ahead.

    The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's liquidity challenges. The company's capital structure is heavily leveraged, with long-term debt of CNY 440.26 million, which could pose a significant financial risk if not managed effectively.

    There are no recent events or filings provided in the data to indicate any significant changes in the company's operations or financial status.

    Key takeaways
    • Immunotech Biopharm Ltd is experiencing significant financial distress, as evidenced by its negative equity and high debt-to-equity ratio.
    • The company is not generating revenue and is reporting substantial operating and net losses, indicating poor profitability.
    • The company's liquidity position is weak, with a current ratio of 0.35, which may hinder its ability to meet short-term obligations.
    • The company's capital structure is heavily reliant on debt, which could pose a significant financial risk if not managed effectively.
    • "margin_outlook_rationale": "The company's margin outlook is negative due to its substantial operating and net losses, indicating poor cost management and pricing power.",
    • "rd_outlook_rationale": "The company's R&D outlook is uncertain as there is no specific data provided on R&D expenditures or projects.",

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$0,74
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    -HK$13.9M
    Net cashⓘ
    -HK$440.3M
    Current ratioⓘ
    0.3
    Debt / equityⓘ
    -31.6
    ROAⓘ
    -38.3%
    ROEⓘ
    16.6%
    Cash conversionⓘ
    42.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    ROE1 657,1 %Best in class
    D/E-31,61Best in class
    Cash Conv0,42Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • Immunotech Biopharm Ltd Market data — financials · 2026-05-27

    Ownership & reference

    Leadership

    • Jian ZhangSenior Vice President
    • Zheng TanExecutive Chairman of the Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6978.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage